Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
daNIS-3 in second-line metastatic colorectal cancer
NL-OMON52122Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nisevokitug and tislelizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (5 arms), sponsored by Novartis. Primary endpoints: Recommended phase 2 dose confirmation and Progression-free survival. Planned start May 2022; status: withdrawn.
02
Drugs
nisevokitugtislelizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON52122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52122.